| Trial ID: | L0285 |
| Source ID: | NCT00279084
|
| Associated Drug: |
Group A: If Necessary, Martial Treatment And / Or Erythropoietin Treatment To Achieve The Goal Of Haemoglobin Level From 110 To 129 G/L.
|
| Title: |
NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|DRUG: GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L
|
| Outcome Measures: |
Primary: Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. | Secondary: Death|Angina|Stroke|Peripheral acute ischemia, vascular angioplasty, surgical vascular bypass, amputation|Heart failure|Pulmonary embolism|Deep venous thrombosis and haemodialysis fistula thrombosis|Bacterial infectious disease|Renal replacement therapy (dialysis or pre-emptive renal transplantation)|Quality of life: SF 36 auto-questionnaire
|
| Sponsor/Collaborators: |
Sponsor: Hospices Civils de Lyon
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
204
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2004-01
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2007-10-04
|
| Locations: |
Joëlle Gillet, Lyon, 69376, France
|
| URL: |
https://clinicaltrials.gov/show/NCT00279084
|
